ArticleScientific reports2025
Dracorhodin perchlorate alleviates sciatic nerve pain in CCI rats by modulating inflammation and promoting nerve repair.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study analyzed protein sequencing from rat samples, categorized into a control group (Chronic Constriction Injury, CCI) and test (treated with dracorhodin perchlorate, DP), The purpose of this study was to identify key target proteins of DP in the treatment of sciatica and elucidate its underlying mechanisms. By comparing the differentially expressed proteins (DEPs) of the two groups at 1, 3, and 7 days post - treatment, it was revealed that DP consistently and significantly downregulated the expression of the Interleukin-6 (IL-6) and the cytokine-Induced neutrophil chemoattractant-3 (CINC-3), while significantly upregulating the expression of the neurotrophic factor ciliary neurotrophic factor (CNTF). Functional enrichment analysis indicated that these DEPs are primarily involved in inflammatory signaling pathways, nerve repair, and the chemotaxis of neutrophils. Validation via Western blot and ELISA demonstrated that the expression levels of IL-6 and CINC-3 were significantly reduced in the DP group, whereas the expression level of CNTF was significantly elevated, thereby confirming the significant therapeutic effect of DP on sciatica. Furthermore, experiments using a zebrafish inflammation model further confirmed that DP could significantly inhibit the recruitment and migration of neutrophils. In summary, this study not only uncovered potential target proteins for DP in the treatment of sciatica but also provided crucial evidence for its mechanism of action, suggesting that DP may effectively alleviate sciatica by downregulating IL-6 and CINC-3, inhibiting neutrophil migration, and upregulating CNTF to promote neurotrophic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.